Vivos Therapeutics (NASDAQ:VVOS) Upgraded at Wall Street Zen

Wall Street Zen upgraded shares of Vivos Therapeutics (NASDAQ:VVOS) from a sell rating to a hold rating in a report released on Saturday.

Several other equities analysts also recently commented on VVOS. Ascendiant Capital Markets cut their target price on Vivos Therapeutics from $6.60 to $6.20 and set a “buy” rating for the company in a research report on Tuesday, April 15th. Industrial Alliance Securities set a $2.25 target price on Vivos Therapeutics in a research report on Tuesday, May 20th. Finally, Alliance Global Partners downgraded Vivos Therapeutics from a “buy” rating to a “neutral” rating in a research report on Tuesday, May 20th.

Vivos Therapeutics Price Performance

Vivos Therapeutics stock opened at $4.76 on Friday. The company has a market capitalization of $28.04 million, a PE ratio of -2.75 and a beta of 7.03. Vivos Therapeutics has a one year low of $1.97 and a one year high of $7.95. The business has a 50 day simple moving average of $3.90 and a 200 day simple moving average of $3.44.

Vivos Therapeutics (NASDAQ:VVOS) last posted its earnings results on Thursday, May 15th. The company reported ($0.45) EPS for the quarter, missing the consensus estimate of ($0.44) by ($0.01). The company had revenue of $3.70 million for the quarter, compared to the consensus estimate of $3.63 million. Vivos Therapeutics had a negative return on equity of 170.43% and a negative net margin of 76.82%. During the same quarter last year, the business earned ($1.63) EPS. Equities analysts anticipate that Vivos Therapeutics will post -1.79 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Vivos Therapeutics

Institutional investors have recently bought and sold shares of the business. EWA LLC bought a new position in Vivos Therapeutics in the 1st quarter valued at $30,000. Commonwealth Equity Services LLC raised its position in Vivos Therapeutics by 23.8% in the 4th quarter. Commonwealth Equity Services LLC now owns 26,000 shares of the company’s stock valued at $112,000 after purchasing an additional 5,000 shares during the last quarter. Geode Capital Management LLC raised its position in Vivos Therapeutics by 55.6% in the 4th quarter. Geode Capital Management LLC now owns 44,827 shares of the company’s stock valued at $192,000 after purchasing an additional 16,025 shares during the last quarter. Cutter & CO Brokerage Inc. raised its position in Vivos Therapeutics by 28.9% in the 1st quarter. Cutter & CO Brokerage Inc. now owns 49,100 shares of the company’s stock valued at $140,000 after purchasing an additional 11,000 shares during the last quarter. Finally, Anson Funds Management LP bought a new position in Vivos Therapeutics in the 4th quarter valued at $1,041,000. Institutional investors own 26.35% of the company’s stock.

About Vivos Therapeutics

Vivos Therapeutics, Inc, a medical technology company, develops and commercializes treatment modalities for patients with dentofacial abnormalities, obstructive sleep apnea (OSA), and snoring in adults. It offers The Vivos Method, a non-invasive, non-surgical, non-pharmaceutical, multi-disciplinary treatment modality for the treatment of dentofacial abnormalities, OSA, and snoring.